Author

admin

Browsing

Rep. Jasmine Crockett, D-Texas, appears to be leaning in on her rising political stardom this week, briefly sharing what appeared to be a fan-made song that referred to the Democratic firebrand as the ‘leader of the future.’

‘Jasmine Crockett, she rises with the dawn. Fighting for justice, her light will never be gone,’ the song went. ‘A voice for the people, standing strong and proud. Infectious with passion, she’ll never bow down. Leader of the future, she’s breaking all the chains. Jasmine you rock girl, keep leading the fight.’

The roughly two-minute-long song was set against what appeared to be photos of Crockett that were lightly animated using artificial intelligence (AI). It ended with a minute of Crockett’s own comments at a recent House hearing.

Fox News Digital observed the video on Crockett’s Instagram Story, where users post highlights that normally disappear after 24 hours. It was also visible on her Instagram Reels tab. Crockett’s official House of Representatives account was listed as a co-author alongside another Instagram account that appears to specialize in AI-generated musical video clips.

Crockett’s account notes that posts are made by her staff unless the letters ‘CWC’ are present. Her account appears to have shared, but not originally posted the video. Fox News Digital reached out to Crockett’s office to ask if she took any part in creating or sanctioning the post.

After Fox News Digital’s inquiry, mention of the video disappeared from Crockett’s page. 

‘A beacon of hope, we know you won’t deceive,’ the song continued at another point. ‘Democratic champion, her mission’s loud and clear. For every single citizen, she’ll always be near. No MAGA could silence the truth she displays. Jasmine, you rock girl, keep leading the fight.’

Crockett has garnered a notable fan base among the progressive left since bursting on the national stage just over two years ago.

She has been known for public comments that have pushed the boundaries of congressional decorum and have even earned her censure threats from her Republican colleagues in the House.

Crockett garnered controversy in late March for referring to Texas Gov. Greg Abbott, who is in a wheelchair, as ‘Governor Hot Wheels.’ She later clarified in a statement that she ‘wasn’t thinking about the governor’s condition,’ but she did not apologize.

She also appeared to cash in on a spat she was part of during a House Oversight Committee hearing last year, when her response to Rep. Marjorie Taylor Greene, R-Ga., claiming Crockett had ‘fake eyelashes,’ was to mock Greene as having a ‘bleach blonde bad built butch body.’

Crockett later moved to trademark the phrase through the U.S. Patent and Trademark Office.

This post appeared first on FOX NEWS

The FBI is taking another look at the cocaine found inside the Biden administration White House in 2023, according to Deputy Director Dan Bongino. 

‘Shortly after swearing in, the Director and I evaluated a number of cases of potential public corruption that, understandably, have garnered public interest. We made the decision to either re-open, or push additional resources and investigative attention, to these cases,’ Bongino said in a post on X. 

‘These cases are the DC pipe bombing investigation, the cocaine discovery at the prior administration’s White House, and the leak of the Supreme Court Dobbs case. I receive requested briefings on these cases weekly and we are making progress. If you have any investigative tips on these matters that may assist us, then please contact the FBI,’ he added. 

The FBI did not immediately respond Tuesday to a request for further comment from Fox News Digital. 

Earlier this year, President Donald Trump said in an interview he believes former President Joe Biden or his son, Hunter Biden, left behind the infamous bag of cocaine at the White House. 

‘So … who actually left the cocaine in the White House?’ The Spectator’s Ben Domenech asked Trump. 

‘Well, either Joe or Hunter,’ Trump responded. ‘Could be Joe, too.’  

The bag of cocaine was discovered on July 2, 2023, in a storage locker near the entrance to the White House’s West Wing.  

The Secret Service discovered the cocaine and launched an investigation, which turned up inconclusive for a suspect. 

‘On July 12, the Secret Service received the FBI’s laboratory results, which did not develop latent fingerprints and insufficient DNA was present for investigative comparisons,’ it said in 2023. ‘Therefore, the Secret Service is not able to compare evidence against the known pool of individuals. The FBl’s evaluation of the substance also confirmed that it was cocaine.’

‘That was such a terrible thing because, you know, those bins are very loaded up with … they’re not clean, and they have hundreds and even thousands of fingerprints,’ Trump also said in the interview. ‘And when they went to look at it, it was absolutely stone cold, wiped dry. You know that, right?’ 

The Biden family, including the former president and Hunter, were not staying at the White House when the cocaine was discovered. Instead, the family was staying at presidential retreat Camp David in Maryland. 

Hunter Biden has a long and well-documented history with substance abuse, and he detailed his hourly need for crack cocaine in his 2021 memoir, ‘Beautiful Things.’ He has since gone through recovery efforts and has been sober since 2019, according to sworn testimony in federal court in 2023. 

Fox News’ Emma Colton contributed to this report. 

This post appeared first on FOX NEWS

Romanian populist Calin Georgescu announced his retirement from politics after being barred from running in the country’s presidential election rerun this month. 

The decision comes after Georgescu ran for president late last year and emerged victorious in the first round of voting. However, a top Romanian court then annulled the result after allegations emerged of electoral violations and Russian interference. Georgescu was later banned from participating in this month’s contest, which was won by pro-European Union candidate Nicusor Dan. 

‘I choose to be a passive observer of public and social life,’ the 63-year-old Georgescu said in a video posted online late Monday. ‘I choose to remain outside any political party structure … I am not affiliated with any political group in any way.’ 

Georgescu – who ran as an independent in November – said he made his decision to take a step back following the conclusion of the presidential race, which for him indicated ‘the sovereignist movement has come to a close.’ 

‘Even though this political chapter has ended, I am convinced that the values and ideals we fought for together remain steadfast,’ he added. ‘My dear ones, I have always said that we would make history, not politics.’ 

In February, prosecutors opened criminal proceedings against Georgescu, accusing him of incitement to undermine the constitutional order, election campaign funding abuses, and founding or supporting fascist, racist, xenophobic, or antisemitic organizations, among other charges. On Tuesday, he was due to appear at the prosecutor’s office in Bucharest. 

Despite what appeared to be a sprawling social media campaign promoting him, Georgescu had declared zero campaign spending in last year’s contest. A Romanian court then made the unprecedented move to annul the election. 

‘This December, Romania straight up canceled the results of a presidential election based on the flimsy suspicions of an intelligence agency and enormous pressure from its continental neighbors,’ Vice President JD Vance said in a speech at the Munich Security Conference in February. 

‘Now, as I understand it, the argument was that Russian disinformation had infected the Romanian elections, but I’d ask my European friends to have some perspective. You can believe it’s wrong for Russia to buy social media advertisements to influence your elections. We certainly do. You can condemn it on the world stage even. But if your democracy can be destroyed with a few hundred thousand dollars of digital advertising from a foreign country, then it wasn’t very strong to begin with,’ Vance added. 

Georgescu sparked controversy for describing Romanian fascist and nationalist leaders from the 1930s and 1940s as national heroes, according to the Associated Press. He has also praised Russian President Vladimir Putin in the past as ‘a man who loves his country’ and has questioned Ukraine’s statehood, but he claims not to be pro-Russian. 

Georgescu has argued the election was ‘canceled illegally and unconstitutionally,’ and after he was barred from the May rerun, he accused the authorities of ‘inventing evidence to justify the theft’ of the elections. 

Earlier this year, thousands of protesters took to the streets of Bucharest in a show of support for Georgescu. 

The Associated Press contributed to this report. 

This post appeared first on FOX NEWS

Former President Joe Biden’s official health reports during his White House tenure did not show signs of aggressive prostate cancer, a Fox News Digital review of the health documents shows. 

Biden, who suffered two brain aneurysms in 1988 that nearly claimed his life, received clean bills of health in 2021, 2023 and 2024, according to former White House physician Dr. Kevin O’Connor’s annual reports on the president’s state of health. 

Biden was scheduled to receive a physical by the end of January 2023 but delayed the evaluation due to a busy travel schedule, the White House reported at the time. The former president had a roughly 15-month period between his 2021 physical and one conducted in February 2023. 

Fox News Digital reviewed the three reports posted by the White House in 2021, 2023 and 2024 and found that there were no signs indicating aggressive prostate cancer was on the horizon for the 46th president — though concerns over skin cancer were a common theme throughout the three reports. 

2021 

Biden’s White House physician released the president’s first annual health report in November 2021, declaring Biden a ‘healthy, vigorous’ man. 

‘President Biden remains a healthy, vigorous, 78-year-old male, who is fit to successfully execute the duties of the Presidency, to include those as Chief Executive, Head of State and Commander in Chief,’ O’Connor wrote in the 2021 report. 

The report included routine screenings of Biden’s heart, eyes and teeth, as well as his occasional gastroesophageal reflux. 

The report noted that Biden also underwent ‘routine’ screenings for both colon cancer and skin cancer. Biden had multiple ‘localized, non-melenoma skin cancers removed’ ahead of his presidency after spending a good deal of time in the sun as a youth, the report stated, but that there were ‘no areas suspicious for skin cancer’ during the 2021 physical. 

The report did find that Biden was increasingly ‘throat clearing’ and coughing during public events. O’Connor stated that Biden had long cleared his throat or coughed during speaking engagements, but such coughing or throat clearing ‘certainly seem more frequent and more pronounced over the last few months.’ 

O’Connor said gastroesophageal reflux was likely the culprit behind Biden’s coughing after conducting multiple lung, oxygen and biological tests. 

The report also noted that Biden’s gait had become noticeably more stiff, which the doctor said required a ‘detailed investigation.’ The stiffened gait was attributed to Biden’s wear and tear on his spine and mild sensory peripheral neuropathy of the feet, which O’Connor said could be addressed with physical therapy and exercise. 

2023 

O’Connor released details on Biden’s second physical as president on Feb. 16, 2023, roughly 15 months after the release of his first presidential physical. The delay between the health assessments was attributed to the president’s busy schedule. 

Biden was notably also diagnosed with COVID-19 in July 2022 during the interim period of his first and second physicals. Biden was reported to have mild symptoms that July and was treated with the antiviral drug Paxlovid. 

The February 2023 physical report found that Biden was in good health and ‘fit’ to serve as president. 

‘President Biden remains a healthy, vigorous 80-year-old male who is fit to successfully execute the duties of the presidency,’ O’Connor wrote in his 2023 health memo.

The report found that Biden’s gait had remained stiff since his last physical, though the issue had not worsened. The report overall found that his heart, lungs, eyes and teeth were all in good health. 

Biden underwent routine skin cancer surveillance, which found a small lesion on the president’s chest that required biopsy. The lesion was removed just a couple of weeks later without issue, a follow-up memo from O’Connor states. 

‘As expected, the biopsy confirmed that the small lesion was basal cell carcinoma,’ Biden’s doctor wrote in a memo after the lesion was removed. ‘All cancerous tissue was successfully removed. The area around the biopsy site was treated presumptively with electrodessication and curettage at the time of biopsy. No further treatment is required.’ 

The 2023 physical health report also provided updates on Biden’s COVID-19 recovery, which the White House doctor said went smoothly in part due to Biden receiving the coronavirus vaccine and two booster shots before the infection. 

2024 

The report on Biden’s final physical examination as president was released Feb. 28, 2024 and again found the president in good health and able to serve as president. 

‘President Biden is a healthy, active, robust 81-year-old male, who remains fit to successfully execute the duties of the Presidency, to include those as Chief Executive, Head of State and Commander in Chief,’ the most recent memo stated. 

Again, vital organs such as the heart and eyes received a clean bill of health, while Biden’s stiff gait did not worsen in the interim since 2023, though the doctor noted ‘arthritic changes’ that were moderate to severe. 

O’Connor reported that he conducted a neurological exam and determined that no cerebral or neurological issues were compounding the president’s stiff gait. The test did support previous findings of peripheral neuropathy of the feet, the report stated. 

The 2024 physical additionally noted that the lesion removed from Biden’s chest the year prior needed no additional treatment, as basal cell carcinoma typically does not metastasize. 

The report added that Biden had been using a continuous positive airway pressure, or CPAP, machine when sleeping after he showed symptoms of obstructive sleep apnea. The president had previously reported similar symptoms in 2008 and 2019, O’Connor stated, but that they subsided after sinus and nasal passage surgeries before his presidency.

He also underwent a root canal that year with no complications. 

Who is Dr. O’Connor? 

Dr. O’Connor has overseen Biden’s health since 2009 and built a close relationship with the president and his family, Fox News Digital previously reported. 

‘I have never had a better commander than Joe Biden,’ O’Connor said in a profile interview with his alma mater, New York Institute of Technology College of Osteopathic Medicine, when Biden served as vice president. ‘All politics aside, he approaches his craft with such honor. He’s 100 percent ‘family first.’ He’s ‘genuinely genuine.’’

O’Connor overwhelmingly remained out of the spotlight during Biden’s tenure until the spring of 2024, when speculation mounted among both conservatives and Democrats that the president’s mental acuity was slipping, with pundits and the media subsequently demanding to hear directly from O’Connor on the state of Biden’s health. 

The White House physician is affectionately known to Biden and his family simply as ‘Doc,’ and was requested by Biden in 2009 to stay on as his physician after serving in the White House Medical Unit under the President George W. Bush administration, according to the profile. 

O’Connor was first appointed to the White House Medical Unit in 2006 for what was intended to be a three-year military assignment, according to his profile published by the New York Institute of Technology College of Osteopathic Medicine, from which he graduated in 1992. 

Instead, ‘Vice President Biden asked O’Connor to stay on,’ the profile continues. 

O’Connor complied, marking the beginning of their doctor-patient relationship that has reportedly evolved into a close relationship with the president’s large family. 

Biden’s 2017 memoir, ‘Promise Me, Dad,’ features the president reflecting on his close relationship with ‘Doc,’ including O’Connor joining the family on their annual vacation to Massachusetts’ Nantucket in his capacity as the White House physician and balking at the family’s ‘browsing extravaganza’ on the island. The White House medical unit always travels with a president to best protect his health and safety.  

The physician’s relationship with the family seemingly grew closer, according to the memoir, when the president’s son, Beau Biden, was diagnosed with brain cancer — which ultimately claimed his life in 2015. 

‘Doc was good with Beau, who was still trying to get his bearings in those first few days. Real fear was starting to creep in. Sometimes Beau would grab him when everybody else was out of earshot to get his honest assessment,’ Biden wrote in the memoir. 

‘‘Whatever it is, this is bad,’ he told Beau, ‘but we’re gonna find out what it is. And once we find out what it is, we will have a plan.’’ 

‘‘Promise?’ Beau asked.’

‘‘Promise.’’ 

In another excerpt, Beau Biden requested O’Connor ‘promise’ to take care of his father if he should die. 

‘‘Seriously, Doc. No matter what happens,” Beau Biden said to O’Connor, according to the book. ‘’Take care of Pop. For real. Promise me. For real.’’

Back in 2018, Joe Biden’s sister-in-law, Sara Biden, described O’Connor as a ‘friend’ who provided medical advice to members of the Biden family beyond the eventual commander in chief. 

‘Colonel O’Connor was actually a friend and he — we would frequently ask for his recommendations if any of us had a medical issue, so it was not uncommon to ask him if he had a recommendation,’ she said in a deposition related to a New York state medical malpractice case involving her daughter, Fox News previously reported. 

The state of Biden’s health now?

Biden’s office announced May 18 that the former president had been diagnosed with an ‘aggressive form’ of prostate cancer, which set off concern that such a cancer should have been discovered sooner. 

‘Last week, President Joe Biden was seen for a new finding of a prostate nodule after experiencing increasing urinary symptoms,’ Biden’s team shared in a statement. ‘On Friday, he was diagnosed with prostate cancer, characterized by a Gleason score of 9 (Grade Group 5) with metastasis to the bone.’ 

‘While this represents a more aggressive form of the disease, the cancer appears to be hormone-sensitive which allows for effective management,’ the statement said. ‘The President and his family are reviewing treatment options with his physicians.’ 

Physicians have remarked that they are ‘shocked’ that the cancer had not been discovered sooner. 

‘Thank God they found it. (Biden is) a fighter. He’s been through a tremendous amount in his life… with his son, with (his) wife, with (his) daughter,’ Fox News senior medical analyst Dr. Marc Siegel said May 19. ‘Two aneurysms, atrial fibrillation. He’s been through a lot health-wise, but I am absolutely shocked that they didn’t find this earlier.’ 

A spokesperson for Biden confirmed to Fox News on May 20 that Biden’s last known prostate-specific antigen (PSA) test, which screens a patient for prostate cancer, was conducted in 2014. 

‘President Biden’s last known PSA was in 2014,’ a Biden spokesperson told Fox News. ‘Prior to Friday, President Biden had never been diagnosed with prostate cancer.’ 

Biden posted to X on May 19 in his first message since publicly revealing the diagnosis to thank supporters. 

‘Cancer touches us all. Like so many of you, Jill and I have learned that we are strongest in the broken places,’ Biden wrote on X, accompanied by a photo with former first lady Jill Biden. ‘Thank you for lifting us up with love and support.’ 

This post appeared first on FOX NEWS

Spearmint Resources Inc. (CSE: SPMT) (OTC Pink: SPMTF) (FSE: A2AHL5) (the ‘Company’ or ‘Spearmint’) announces that it intends to complete a consolidation of its issued and outstanding common shares (the ‘Shares’) on the basis of one new Share (a ‘Post-consolidated Share’) for every ten currently outstanding Shares (the ‘Consolidation’). The Company also announces it intends to change its name and its trading symbol in connection with the proposed Consolidation.

Completion of the Consolidation, name change and symbol change are subject to approval by the Canadian Securities Exchange (the ‘CSE‘). The effective date of the Consolidation, name change and symbol change will be announced in a subsequent news release.

It is anticipated that the Consolidation will reduce the number of outstanding Shares from 287,828,583 Shares to approximately 28,782,858 Post-consolidated Shares, subject to adjustment for rounding. The Board of Directors of the Company believes that the consolidation of the Shares will both enhance the marketability of the Company as an investment and better position the Company to raise the funds necessary to execute the Company’s business plan.

No fractional Post-consolidated Shares will be issued as a result of the Consolidation. As required under the Business Corporations Act (BC), any fractional Shares remaining after the Consolidation that are less than one half of a Share will be cancelled and any fractional Shares that are at least one half of a Share will be rounded up to one whole Share.

The exercise price and number of Shares of the Company, issuable upon the exercise of outstanding options and warrants and conversion of outstanding convertible debentures, will be proportionally adjusted upon the implementation of the proposed Consolidation in accordance with the terms thereof.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information
Tel: 1604646-6903
www.spearmintresources.ca

info@spearmintresources.ca

‘James Nelson’
President
Spearmint Resources Inc.

Forward-Looking Statements

This news release contains forward-looking information which is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ from those projected in the forward-looking statements. Forward-looking statements in this press release include that the Company intends to consolidate its share capital. These forward-looking statements are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. Risks that could change or prevent these statements from coming to fruition include that the Company may not obtain approval for the Consolidation from the CSE. The forward-looking information contained herein is given as of the date hereof and the Company assumes no responsibility to update or revise such information to reflect new events or circumstances, except as required by law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/253436

News Provided by Newsfile via QuoteMedia

This post appeared first on investingnews.com

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

Saga Metals Corp. (the ‘Company’ or ‘SAGA’) (TSXV: SAGA) (OTCQB: SAGMF) (FSE: 20H) a North American exploration company focused on critical mineral discovery in Canada, is pleased to announce that it has closed a first tranche (the ‘ First Tranche ‘) of its non-brokered private placement announced on May 2, 2025 (the ‘ Offering ‘) for gross proceeds of $1,239,700.10. The Company has also received a 30-day extension to close the Offering from the TSX Venture Exchange, and accordingly expects to close the final tranche of the Offering on or before June 25, 2025.

On closing of the First Tranche, the Company received gross proceeds of $444,200.10 from the issuance of 1,480,667 flow-through units at a price of $0.30 per unit (‘ FT Units ‘) and $795,500 from the issuance of 3,182,000 hard dollar units at a price of $0.25 per unit (‘ HD Units ‘).

Each FT Unit consists of one flow-through common share (a ‘ FT Share ‘) as defined in subsection 66(15) of the Income Tax Act (Canada) (the ‘ Tax Act ‘), and one transferable common share purchase warrant (a ‘ Warrant ‘). Each Warrant will entitle its holder to purchase one common share in the capital of the Company (a ‘ Warrant Share ‘) at a price of $0.50 for 24 months from the closing date of the Offering (the ‘ Closing Date ‘). The Warrants and the Warrant Shares underlying the FT Units will not qualify as ‘flow-through shares’ under the Tax Act.

Each HD Unit consists of one common share (a ‘ HD Share ‘) and one Warrant.

All securities issued in connection with the First Tranche are subject to a hold period of four months and one day following the Closing Date pursuant to applicable securities laws.

In connection with the First Tranche, the Company paid an aggregate of $31,710.01 in finder’s fees and issued 108,616 finder’s warrants (each, a ‘ Finder’s Warrant ‘) to certain finders. Each Finder’s Warrant entitles the holder thereof to purchase one common share of the Company at a price of $0.50 per share for a period of 24 months from its date of issue.

Each of the Warrants and Finder’s Warrants will be subject to the right of the Company to accelerate the expiry date of the Warrants and Finder’s Warrants to a date that is 30 days following dissemination of a news release announcing such acceleration if, at any time, after the Closing Date, the closing price of the Company’s common shares equals or exceeds $0.75 for a period of ten consecutive trading days on the TSX Venture Exchange.

The gross proceeds from the FT Units will be used by the Company for ‘Canadian exploration expenses’ that are ‘flow-through critical mineral mining expenditures’ (as such terms are defined in the Tax Act) on the Company’s Labrador, Canada properties. The net proceeds of the HD Units will be used by the Company for administrative and general working capital.

Certain insiders of SAGA participated in the First Tranche, acquiring an aggregate of 442,000 HD Units for aggregate gross proceeds of $110,500. Participation of such insiders in the Offering constitutes a ‘related party transaction’ as defined under Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions (‘ MI 61-101 ‘) and is exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 as neither the fair market value of the securities issued to the insiders nor the consideration paid by the insiders exceeded 25% of SAGA’s market capitalization.

The securities of SAGA have not been and will not be registered under the United States Securities Act of 1933, as amended (the ‘ U.S. Securities Act ‘), or any state securities laws, and may not be offered or sold, within the United States, unless exemptions from the registration requirements of the U.S. Securities Act and applicable state securities laws are available.

No securities regulatory authority has reviewed or approved of the contents of this news release. This news release does not constitute an offer to sell or a solicitation of an offer to buy any securities of SAGA in any jurisdiction in which such offer, solicitation or sale would be unlawful.

About Saga Metals Corp.

Saga Metals Corp. is a North American mining company focused on the exploration and discovery of critical minerals that support the global transition to green energy. The company’s flagship asset, the Double Mer Uranium Project, is located in Labrador, Canada, covering 25,600 hectares. This project features uranium radiometrics that highlight an 18km east-west trend, with a confirmed 14km section producing samples as high as 0.428% U 3 O 8 and uranium uranophane was identified in several areas of highest radiometric response (2024 Double Mer Technical Report).

In addition to its uranium focus, SAGA owns the Legacy Lithium Property in Quebec’s Eeyou Istchee James Bay region. This project, developed in partnership with Rio Tinto, has been expanded through the acquisition of the Amirault Lithium Project. Together, these properties cover 65,849 hectares and share significant geological continuity with other major players in the area, including Rio Tinto, Winsome Resources, Azimut Exploration, and Loyal Lithium.

SAGA also holds additional exploration assets in Labrador, where the company is focused on the discovery of titanium, vanadium, and iron ore. With a portfolio that spans key minerals crucial to the green energy transition, SAGA is strategically positioned to play an essential role in the clean energy future.

On Behalf of the Board of Directors

Mike Stier, Chief Executive Officer

For more information, contact:
Saga Metals Corp.
Investor Relations
Tel: +1 (778) 930-1321
Email: info@sagametals.com
www.sagametals.com

The TSX Venture Exchange has not reviewed and does not accept responsibility for the accuracy or adequacy of this release. Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Disclaimer

This news release contains forward-looking statements within the meaning of applicable securities laws that are not historical facts. Forward-looking statements are often identified by terms such as ‘will’, ‘may’, ‘should’, ‘anticipates’, ‘expects’, ‘believes’, and similar expressions or the negative of these words or other comparable terminology. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. In particular, this news release contains forward-looking information pertaining to the Company’s plans and objectives in respect of the terms and conditions of the Offering, the gross proceeds of the Offering, the use of proceeds from the Offering, and the anticipated closing dates of additional tranches of the Offering and the Offering. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include, but are not limited to, changes in the structure of the Offering, the state of equity and debt markets, fluctuations in commodity prices, delays in obtaining required regulatory or governmental approvals, environmental risks, limitations on insurance coverage, risks and uncertainties involved in the mineral exploration and development industry, and the risks detailed in the Company’s final prospectus in Manitoba and amended and restated final prospectus for British Columbia, Alberta and Ontario dated August 30, 2024, filed under its SEDAR+ profile at www.sedarplus.ca, and in the continuous disclosure filings made by the Company with securities regulations from time to time. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements only as expressly required by applicable securities law.

News Provided by GlobeNewswire via QuoteMedia

This post appeared first on investingnews.com

Blue Sky Uranium (TSXV:BSK,OTC:BKUCF)provides investors with a compelling opportunity to gain exposure to the uranium market through its strategic foothold in Argentina’s emerging uranium sector. Backed by a substantial resource base, robust project economics, and a strong joint venture partnership, the company has a clear pathway to potential production.

Blue Sky Uranium is positioning itself as a leading force in uranium exploration and development in Argentina. As part of the renowned Grosso Group—pioneers in Argentine mineral exploration since 1993 and contributors to four major mineral discoveries—Blue Sky leverages decades of in-country expertise and well-established local partnerships.

The company’s flagship Amarillo Grande Project is a unique, company-led discovery marking Argentina’s newest uranium-vanadium district. Spanning over 145 kilometers and covering more than 300,000 hectares in Rio Negro Province, this district-scale project hosts the largest NI 43-101-compliant uranium resource in Argentina at its Ivana deposit. With this strategic asset, Blue Sky is well-positioned to become the country’s first domestic uranium supplier, supporting a growing nuclear energy program that currently relies entirely on imported fuel.

Company Highlights

  • Significant Uranium Resource: Controls the largest NI 43-101 compliant uranium resource in Argentina with 17 Mlbs U3O8 in indicated resources and 3.8 Mlbs in inferred resources, plus valuable vanadium credits.
  • Low-cost Production Potential: Near-surface mineralization with no blasting required, hosted in loosely consolidated sediments, making for potentially low mining costs.
  • Strategic JV Partnership: Secured an earn-in agreement with COAM to advance the Ivana deposit with no funding required by Blue Sky through development. COAM will spend up to US$35 million to earn up to a 49.9 percent interest, and can further earn up to 80 percent by funding development costs to production (up to US$160 million).
  • Strong Uranium Market Fundamentals: Global uranium market faces supply deficits with increasing demand from nuclear power generation, with prices strengthening significantly since 2023.
  • Domestic Market Opportunity: Argentina has three operational nuclear plants with others under construction or planned, yet imports all uranium for fuel. National legislation guarantees purchase of domestically produced uranium.
  • ISR Project Pipeline: New projects in the Neuquen Basin provide future growth through potential in-situ recovery operations, a method that produces 57 percent of the world’s uranium with minimal environmental impact.

This Blue Sky Uranium profile is part of a paid investor education campaign.*

Click here to connect with Blue Sky Uranium (TSXV:BSK) to receive an Investor Presentation

This post appeared first on investingnews.com

(TheNewswire)

Edmonton, Alberta May 27, 2025 TheNewswire – Bitcoin Well Inc. (‘ Bitcoin Well ‘ or the ‘ Company ‘) ( TSXV: BTCW; OTCQB: BCNWF ), the non-custodial bitcoin business on a mission to enable independence announces a first-of-its-kind Nostr integration to allow Bitcoin Well customers in the USA to purchase bitcoin directly from their Nostr profile.

Key points:

How it Works:

  • The purchase uses the customers Cash Balance, and bitcoin is sent to an existing Lightning Wallet for security.

Why it Matters:

  • It aligns with the company’s mission to simplify self-custody bitcoin purchases.

Nostr’s Role:

    Impact:

      This move continues to position Bitcoin Well as a leader in freedom technologies by making bitcoin in self custody the standard. For detailed information keep reading, or visit https://bitcoinwell.com/blog/buy-bitcoin-with-nostr

      Why does this matter?

      Social media, specifically Nostr, is one of the most impactful technologies of our generation. Our lives, our communities and our personalities have transitioned to the digital realm. Bitcoin Well has now enabled everyone in the USA to buy bitcoin safely, directly from their Nostr account.

      In doing this, Bitcoin Well has become the easiest place to buy bitcoin! With a simple message, our customers in the USA can now purchase bitcoin in a matter of seconds; without logging in to their Bitcoin Well account.

      ‘This is a great achievement for our team!’ said Adam O’Brien, founder and CEO of Bitcoin Well. ‘We are deeply committed to make buying bitcoin directly to self custody better than using a custodial exchange. This is a huge step in the right direction. We are meeting bitcoiners where they are and allowing them to buy bitcoin safely.’

      How does it work?

      Once a customer links their npub (the social network identifier used by the Nostr protocol) to their Bitcoin Well account from their profile page , they can DM the Bitcoin Well Nostr profile with the command words to purchase bitcoin. The command words are:

      • /buy $21.00 (or any dollar amount)

      • /stack 69,000 sats (or any amount of sats)

      After a simple ‘/confirm’ response, the customer’s Cash Balance in their Bitcoin Well account will be used to buy bitcoin, and the bitcoin will be sent to their predetermined payment address over the Lightning Network.

      To maintain security, bitcoin can only be sent to a Lightning Wallet which has already been added to their Bitcoin Well account.

      What is Nostr?

      Nostr is a decentralized social media protocol which is censorship resistant and runs on a network of relays, rather than centralized servers. This means that the users of the platform control the posts (known as ‘notes’) rather than the owner of the social media platform. This is particularly impactful for the Company because it means we have full control over our message servers; which hasn’t been the case in the past.

      Historically, our messaging platforms have prohibited us from creating a ‘text to buy’ type of service. Even our payment providers have been limited in the past. With the addition of the Nostr protocol we can be certain that this level of censorship will not impact us, or our customer’s ability to buy bitcoin. Furthermore, there is an added layer of protection for the customer’s privacy.

      About Bitcoin Well

      Bitcoin Well is on a mission to enable independence. We do this by making bitcoin useful to everyday people to give them the convenience of modern banking and the benefits of bitcoin. We like to think of it as future-proofing money. Our existing Bitcoin ATM and Online Bitcoin Portal business units drive cash flow to help fund this mission.

      Join our investor community and follow us on Nostr , , and to keep up to date with our business.

      Bitcoin Well contact information

      To book a virtual meeting with our Founder & CEO Adam O’Brien please use the following link: https://bitcoinwell.com/meet-adam

      For additional investor & media information, please contact:

      Adam O’Brien

      Tel: 1 888 711 3866

      ir@bitcoinwell.com

      Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release .

      Forward-looking information

      Certain statements contained in this news release may constitute forward-looking information, which is often, but not always, identified by the use of words such as ‘anticipate’, ‘plan’, ‘estimate’, ‘expect’, ‘may’, ‘will’, ‘intend’, ‘should’, or the negative thereof and similar expressions. All statements herein other than statements of historical fact constitute forward-looking information including, but not limited to, statements in respect of Bitcoin Well’s business plans, strategy and outlook. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking information including, but not limited to, the risk factors described in Bitcoin Well’s annual information form and management’s discussion and analysis for the year ended December 31, 2024. Forward-looking information should not be unduly relied upon. Any forward-looking information contained in this news release represents Bitcoin Well’s expectations as of the date hereof and is subject to change. Bitcoin Well disclaims any intention or obligation to revise any forward-looking information, except as required by applicable securities legislation.

      Copyright (c) 2025 TheNewswire – All rights reserved.

      News Provided by TheNewsWire via QuoteMedia

      This post appeared first on investingnews.com

      Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (‘Cardiol’ or the ‘Company’), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces that the Company’s virtual Annual General Meeting of Shareholders (the ‘AGM’) will be webcast on May 28, 2025, at 4:30 p.m. EDT.

      Cardiol Therapeutics’ 2025 AGM

      When: May 28, 2025, at 4:30 p.m. EDT
      Where: Virtual meeting only via live audio webcast online at: web.lumiagm.com/226536161

      Additional information about the AGM, including details on how to participate and vote, is available on the Company’s website at cardiolrx.com/investors/events-presentations/.

      About Cardiol Therapeutics

      Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company’s lead small molecule drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure.

      Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration (‘US FDA’) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease of the pericardium which is associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, and results in physical limitations, reduced quality of life, emergency department visits, and hospitalizations, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299). The ongoing ARCHER trial (NCT05180240) is a Phase II study in acute myocarditis, an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in people less than 35 years of age. The US FDA has granted Orphan Drug Designation to CardiolRx for the treatment of pericarditis, which includes recurrent pericarditis.

      Cardiol is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure – a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding $30 billion annually.

      For more information about Cardiol Therapeutics, please visit cardiolrx.com.

      Cautionary statement regarding forward-looking information:

      This news release contains ‘forward-looking information’ within the meaning of applicable securities laws. All statements, other than statements of historical fact, that address activities, events, or developments that Cardiol believes, expects, or anticipates will, may, could, or might occur in the future are ‘forward-looking information’. Forward looking information contained herein may include, but is not limited to statements regarding the Company’s focus on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, the Company’s intended clinical studies and trial activities and timelines associated with such activities, including the Company’s plan to complete the Phase III study in recurrent pericarditis with CardiolRx, and the Company’s plan to advance the development of CRD-38, a novel subcutaneous formulation of cannabidiol intended for use in heart failure. Forward-looking information contained herein reflects the current expectations or beliefs of Cardiol based on information currently available to it and is based on certain assumptions and is also subject to a variety of known and unknown risks and uncertainties and other factors that could cause the actual events or results to differ materially from any future results, performance or achievements expressed or implied by the forward looking information, and are not (and should not be considered to be) guarantees of future performance. These risks and uncertainties and other factors include the risks and uncertainties referred to in the Company’s Annual Information Form filed with the Canadian securities administrators and U.S. Securities and Exchange Commission on March 31, 2025, available on SEDAR+ at sedarplus.ca and EDGAR at sec.gov, as well as the risks and uncertainties associated with product commercialization and clinical studies. These assumptions, risks, uncertainties, and other factors should be considered carefully, and investors should not place undue reliance on the forward-looking information, and such information may not be appropriate for other purposes. Any forward-looking information speaks only as of the date of this press release and, except as may be required by applicable securities laws, Cardiol disclaims any intent or obligation to update or revise such forward-looking information, whether as a result of new information, future events, or results, or otherwise. Investors are cautioned not to rely on these forward-looking statements and are encouraged to read the Supplement, the accompanying Base Prospectus and the documents incorporated by reference therein.

      For further information, please contact:
      Trevor Burns, Investor Relations +1-289-910-0855
      trevor.burns@cardiolrx.com

      To view the source version of this press release, please visit https://www.newsfilecorp.com/release/253470

      News Provided by Newsfile via QuoteMedia

      This post appeared first on investingnews.com

      Despite assurances from Trump administration officials that farmers will not be impacted by its attempts to reduce environmental chemical exposure from foods, agricultural leaders have been expressing concern that the move will explode costs for farmers and more than double the cost of food. 

      The administration’s Make America Healthy Again (MAHA) Commission, made up of many of President Donald Trump’s political appointees and closest policy advisors, released an assessment strategizing how they will tackle childhood chronic diseases, such as obesity and mental health challenges. Part of the report’s focus is on children’s chemical exposure from our foods, which the report says is linked to developmental issues and chronic diseases.   

      Amid the report’s release, farm groups have expressed concern over the MAHA agenda’s focus on pesticides. They have said that if the administration starts clamping down on widely used pesticides, crop yields would decline, input costs would surge and food costs would more than double.

      ‘Farmers are already facing a host of challenges—uncertainty about their access to critical crop protection products shouldn’t be added to the list,’ said Elizabeth Burns-Thompson, Executive Director of the Modern Ag Alliance. ‘Crop protection tools are not only safe, they are essential to food security, affordability, and the survival of family farms all across this country. Losing access to these critical inputs would be a devastating setback to American agriculture.’

      Officials from the MAHA Commission sought to reassure farmers at an event releasing their assessment on childhood chronic diseases on Thursday. Agriculture Secretary Brooke Rollins said that ‘at the center’ of the MAHA agenda is ‘making American agriculture great again.’

      ‘We love our farmers, and we want to pay respect to our farmers. And we always will,’ President Trump added at the Thursday event from the White House. ‘We won the farmers by a lot in the election, and every election, all three elections – and we won by a lot. I will never forget that. And they are foremost in our thought.’

      But some farmers are still expressing concern.

       

      ‘The Make America Healthy Again Report is filled with fear-based rather than science-based information about pesticides. We are deeply troubled that claims of this magnitude are being made without any scientific basis or regard for a long history of EPA expert evaluations of these products,’ the National Corn Grower’s Alliance (NCGA) said. ‘We call on the administration to respect the existing body of science on pesticides and, moving forward, to include America’s farmers in discussion as this process evolves.’ 

      According to a statement put out by the Modern Ag Alliance, pesticides are ‘rigorously tested’ by the federal government, noting that in the case of glyphosate – mentioned multiple times in the MAHA report – it is one of the most thoroughly studied pesticides of its kind. 

      They said that if the MAHA report drives future policy decisions it would hurt farmers and more than double the cost of food.

      ‘Without glyphosate—the most widely used weed-fighting tool by U.S. farmers—crop yields would decline, input costs would surge by 150%, and food inflation would more than double,’ the group said. ‘When Sri Lanka prohibited the use of synthetic pesticides and fertilizers in 2021, crop yields fell by over 50%, forcing the government to import massive amounts of food just to meet basic needs. We should be focused on moving American agriculture—and the country—forward.’

      Health Secretary Robert F. Kennedy Jr., who has been a vocal opponent against the dangerous health impacts of under-regulated pesticides even before he was the MAHA Commission’s leader, said last week in a Senate hearing that ‘we cannot take any step that will put a single farmer in this country out of business.’

      ‘There’s a million farmers who rely on glyphosate,’ he said. ‘100% of corn in this country relies on glyphosate. We are not going to do anything to jeopardize that business model.’ 

      The MAHA report reiterates the economic importance of protecting farmers, but it also lists glyphosate in an infographic of ‘Chemical Classes and Common Exposure Pathways’ and says research studies have shown it can cause a range of health effects. It also lists atrazine and other chemicals as dangerous to childhood health.   

      MAHA Commission officials have said that part of the administration’s focus will be a return to the gold standard of science, but the NCGA said the focus on certain widely-used pesticides, such as atrazine and glyphosate, goes against ‘decades of extensive research and testing.’

      ‘If the administration’s goal is to bring more efficiency to government, then why is the secretary of Health and Human Services duplicating efforts by raising questions about pesticides that have been answered repeatedly through research and reviews by federal regulatory bodies?’ the group questioned.

      Jennifer Galardi, a senior policy analyst focused on health and wellness issues at the Heritage Foundation, took a more balanced view of the MAHA commission’s strategy towards pesticides like glyphosate, noting that it appeared to thread the needle between supporting farmers and trying to ensure America’s food supply is safe and free of chemicals that could impact child health. 

      ‘The MAHA Commission Report seems to carefully examine competing issues in a very complex agricultural debate: the potential that crop protection tools as they’re referred to in the report may cause adverse health outcomes and the desire to protect the economic interests of farmers and the country,’ Galardi said. ‘However, everyone should agree that the companies that manufacture products such as glyphosate and GMO’s shouldn’t have undue influence over the research upon which sound policy is based. The American public should demand transparency around these decisions.’

      Galardi posited that, due to the tension around the issue of pesticides, the MAHA Commission may decide to go after ‘low-hanging fruit,’ such as improving children’s diets and lack of physical activity, which, she said, are big drivers of obesity and metabolic dysfunction.

      In response to this article, a USDA spokesperson sent the following statement from Secretary Rollins:

      ‘We must do more to improve the health outcomes of our kids and families, and President Trump knows agriculture is at the heart of the solution. America’s farmers and ranchers dedicate their lives to the noble cause of feeding their country and the world, and in doing so have created the safest and most abundant and affordable food supply in the world. We are working to make sure our kids and families are consuming the healthiest food we produce. I look forward to continuing to work with Secretary Kennedy and other members of the MAHA Commission to improve our nation’s health.’

      White House spokesman Kush Desai, in a separate statement, echoed Rollins’ sentiment about the importance of agriculture and farmers when it comes to executing the MAHA mission. He also reiterated that the MAHA movement is grounded in ‘Gold Standard of Science.’

      ‘The guiding principle of President Trump’s movement to Make America Healthy Again is the Gold Standard of Science, and everyone from America’s farmers to everyday parents are critical for the success of this movement,’ Desai said. ‘The MAHA Commission’s report is a historic step by our government to, for the first time, comprehensively review the latest evidence and research of what we know – and what we don’t know – is driving the health crisis afflicting America’s children.’

      This post appeared first on FOX NEWS